Figure 6.
![(A) ‘Diluted' hexasaccharide containing only the key residues necessary to elicit an immune response to Group B Streptococcus type III [54–56]. (B) Group A CPS tethered to the ScpA193 protein conferring bivalent immunity [50,51].](https://port.silverchair-cdn.com/port/content_public/journal/biochemsoctrans/49/5/10.1042_bst20210766/1/bst-2021-0766c.06.png?Expires=1716602365&Signature=scdCX6B6x8qpS1OTsS5AE8BVtyXILaloY9S9QQLPGE7QIihz~mmULdUVIxJCPUkmiQt-JZCZc5JgJQCxuwFkC7J5~fIlhYTeDVEpfgy8vYeqKLE27dD~xSULdf0X1BYgIkIDzVAyr~p4HwYx8YIzK0VhFYscSKwaXYDmba~FORKarRalAUdmBrJ6KjWxM14Gxbn3HkUbqnCZY2qCiTsrIPgCD79Lo6NoVDHsmRh5CsVQxjT7yh~NITKOKqVK65dxA8uchr~BS-xA-l-d0Sj9vBW~H3fa7qgsh4mqeb8JwDd57Ya8t7nx0Lkcjbbnd~KaUWfukatfu8JhzwTjCrzRHg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Glycotope and a semisynthetic vaccine conjugate from capsular polysaccharides of Group A and B Streptococcus.
(A) ‘Diluted' hexasaccharide containing only the key residues necessary to elicit an immune response to Group B Streptococcus type III [54–56]. (B) Group A CPS tethered to the ScpA193 protein conferring bivalent immunity [50,51].